A. Sorace

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A. G. Sorace, A. Sorace, Anna G. Sorace, Anna Goblirsch Sorace, Anna Sorace, Anna G Sorace
Publication record
172 papers · 2,241 citations · H-index 26

PAPERS

Quantitative dynamic granzyme B PET imaging to characterize novel combination immunotherapy response in preclinical glioblastoma models
20260 citationsauthor #14
PREDICTING COMBINED RADIOTHERAPY-IMMUNOTHERAPY OUTCOMES IN MURINE TNBC VIA BAYESIAN CALIBRATION OF BIOLOGY-BASED ODE MODELS AND [89ZR]-CD8 PET IMAGE
20260 citationsauthor #3
Preclinical Comparison of 18F-Labeled Amino Acids Targeting Different Transporter Systems for PET Imaging of Triple-Negative Breast Cancer.
20260 citationsauthor #5
Comparison of 5-aminolevulinic acid and MMP-14 targeted peptide probes in preclinical models of GBM
20252 citationsauthor #8
Strain Promotes Triple Negative Breast Cancer Proliferation and Migration Via VEGFR-2
20250 citationsauthor #5
PET Imaging of Diabetes-Induced Alterations in Metabolism and Immune Activation
20250 citationsauthor #10
Modeling tumor dynamics and predicting response to therapies in a murine pancreatic cancer model
20250 citationsauthor #5
Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI
20257 citationsauthor #13
Employing nullclines to balance treatment efficacy and neurotoxicity for sustained tumor control.
20250 citationsauthor #3
Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer
20252 citationsauthor #10
[18F]-FLT-PET to evaluate how the sequencing of chemotherapies impacts the efficacy of combination treatment in mouse models of triple-negative breast cancer
20250 citationsauthor #8
PET imaging of 52Mn labeled DOTATATE and DOTAJR11
20253 citationsauthor #5
Challenges and Opportunities in High-Grade Glioma Management and Imaging-Based Response Monitoring During Novel Immunotherapies
20252 citationsauthor #8
Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer
20252 citationsauthor #9
Modeling tumor dynamics and predicting response to chemo-, targeted-, and immune-therapies in a murine model of pancreatic cancer
20250 citationsauthor #5
Modeling the Effects of Combination Immunotherapy on Triple-Negative Breast Cancer in Syngeneic Mice from PET Imaging of CD4+ and CD8+ Cells.
20250 citationsauthor #4
Abstract 1120: CD8 ImmunoPET imaging identifies an immunogenically active tumor microenvironment following radiotherapy in primary TNBC
20240 citationsauthor #6
A mouse model of Zhu-Tokita-Takenouchi-Kim syndrome reveals indispensable SON functions in organ development and hematopoiesis
20243 citationsauthor #20
Abstract 4154: PET imaging to characterize the tumor microenvironment in a breast cancer model of obesity
20240 citationsauthor #7
Abstract PS05-04: [89Zr]Trastuzumab-PET/MRI to Characterize HER2+ Breast Cancer: A Quantitative Approach on Tumor Heterogeneity
20240 citationsauthor #10
Spatial multiplexing and omics
202420 citationsauthor #4
[89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models
202410 citationsauthor #14
Dual anti-HER2/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC
20247 citationsauthor #11
Author Correction: Spatial multiplexing and omics
20240 citationsauthor #4
[18F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response.
20243 citationsauthor #5
472 Utility of [89Zr]Trastuzumab-PET/MRI Imaging for Quantitative Assessment of Tumor Heterogeneity In HER2+ Breast Cancer
20240 citationsauthor #10
Abstract 3980: Investigating the role of host obesity in promoting immunotherapy resistance
20240 citationsauthor #6
Abstract PO3-07-10: Advanced CD8 ImmunoPET imaging predicts radiation response in primary TNBC
20240 citationsauthor #6
PET imaging of [52 Mn]Mn-DOTATATE and [52 Mn]Mn-DOTA-JR11
20240 citationsauthor #5
Evaluating the immunologically “cold” tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models
202411 citationsauthor #14
A mouse model of ZTTK syndrome reveals indispensable SON functions in organ development and hematopoiesis
20231 citationsauthor #19
Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy.
20232 citationsauthor #7
Abstract 3576: Molecular imaging of CD8 infiltration following combination immunotherapy in preclinical glioblastoma
20230 citationsauthor #10
Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging: Challenges and Opportunities.
20234 citationsauthor #6
Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
20238 citationsauthor #6
Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer
20232 citationsauthor #5
[89Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
202313 citationsauthor #5
Cdk5 mediates rotational force-induced brain injury
20238 citationsauthor #7
Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models
20233 citationsauthor #7
Evaluation of a CD206-Targeted Peptide for PET Imaging of Macrophages in Syngeneic Mouse Models of Cancer.
202315 citationsauthor #10
Utility of Targeted Positron Emission Tomography Imaging to Predict Schwannoma Growth in a Murine Tumor Model
20230 citationsauthor #3
Abstract 3990: Imaging molecular alterations during tucatinib response in preclinical models of HER2+ breast cancer
20231 citationsauthor #3
Voltage-Gated Sodium Channel NaV1.7 Inhibitors with Potent Anticancer Activities in Medullary Thyroid Cancer Cells
202312 citationsauthor #10
Determination of Flap Survival Isolated From Wound Bed Vasculature Using a Murine Axial Flap Model
20231 citationsauthor #7
Optimizing combination therapy in a murine model of HER2+ breast cancer.
202215 citationsauthor #3
Abstract 2482: Evaluating immune checkpoint blockade treatment efficacy via [89Zr]-CD4 and [89Zr]-CD8 PET imaging in breast cancer mouse models
20221 citationsauthor #11
Analysis of simplicial complexes to determine when to sample for quantitative DCE MRI of the breast
20224 citationsauthor #5
Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer
202219 citationsauthor #5
Abstract P3-02-09: Three timepoint pharmacokinetic modeling to incorporate within standard of care MRI breast exams
20220 citationsauthor #5
Characterization and Preclinical Treatment of Rotational Force-Induced Brain Injury
20220 citationsauthor #7
Systemic checkpoint blockade by PD-L1 single-chain antibody confers potent anti-tumor immunity and long-term survival.
20222 citationsauthor #6
Abstract 5050: Optimizing delivery of combination targeted and chemotherapy in a murine model of HER2+ breast cancer
20220 citationsauthor #3
Mathematical Model of Triple-Negative Breast Cancer in Response to Combination Chemotherapies
20222 citationsauthor #7
Evaluating the Accuracy of FUCCI Cell Cycle In Vivo Fluorescent Imaging to Assess Tumor Proliferation in Preclinical Oncology Models
20223 citationsauthor #7
Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast Cancer
20229 citationsauthor #10
Abstract P3-03-03: Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
20220 citationsauthor #2
Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer
202248 citationsauthor #9
Abstract PS3-07: Molecular imaging of hypoxia and granzyme B alterations during combination treatment with immunotherapy in triple negative breast cancer
20210 citationsauthor #5
The rate of breast fibroglandular enhancement during dynamic contrast-enhanced MRI reflects response to neoadjuvant therapy.
20213 citationsauthor #5
92418 Molecular imaging of the tumor microenvironment to predict response to combination treatment with immunotherapy in triple negative breast cancer
20210 citationsauthor #5
Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting
202139 citationsauthor #5
Abstract PS3-03: [89Zr]-pertuzumab pet imaging reveals paclitaxel treatment efficacy is positively correlated with her2 expression in human breast cancer xenograft mouse models
20211 citationsauthor #6
Abstract PS10-21: Identifying efficacy of targeted HER2 antibodies in sensitization of HER2 positive breast cancer to fractionated radiation
20210 citationsauthor #7
Predicting Schwannoma Growth in a Tumor Model Using Targeted Imaging
20216 citationsauthor #2
Abstract 3138: Identification of therapy-sensitive tumor phenotypes using quantitative MRI habitats in a preclinical model of HER2+ breast cancer
20210 citationsauthor #7
Team Science 84357 A TL 1 Team Approach to Integrating Mathematical and Biological Models to Target Myeloid-Derived Immune Cells in Glioblastoma
20210 citationsauthor #6
Abstract 3058: Molecular imaging of hypoxia to evaluate synergy between HER2 targeted therapy and fractionated radiation in murine models of HER2+ breast cancer
20210 citationsauthor #6
[89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models
202114 citationsauthor #9
RORγt-Expressing Pathogenic CD4+ T Cells Cause Brain Inflammation during Chronic Colitis
202125 citationsauthor #8
Navigating parental leave as a leader in radiology: Commentary on challenges and strategies.
20215 citationsauthor #3
Hyperintensity of integrin‐targeted fluorescence agent IntegriSense750 accurately predicts flap necrosis compared to Indocyanine green
20211 citationsauthor #4
Quantitative Longitudinal Imaging Reveals that Inhibiting Hedgehog Activity Alleviates the Hypoxic Tumor Landscape
20214 citationsauthor #7
Abstract PS13-18: Predicting breast cancer response to neoadjuvant therapies using a mathematical model individualized with patient-specific magnetic resonance imaging data: Preliminary Results
20210 citationsauthor #6
Abstract PS3-26: Characterizing errors in perfusion model parameters derived from retrospectively abbreviated quantitative DCE-MRI data
20210 citationsauthor #6
Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
202113 citationsauthor #2
Characterizing Errors in Pharmacokinetic Parameters from Analyzing Quantitative Abbreviated DCE-MRI Data in Breast Cancer
20212 citationsauthor #5
18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
202133 citationsauthor #8
Author Correction: Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model
20211 citationsauthor #13
Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model
202121 citationsauthor #13
β-eye: A benchtop system for in vivo molecular screening of labeled compounds.
20211 citationsauthor #14
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
202022 citationsauthor #7
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
20200 citationsauthor #7
Abstract P1-18-25: Quantifying the effects of combination trastuzumab and radiation therapy in HER2 positive breast cancer under normoxic and hypoxic conditions
20200 citationsauthor #3
CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro
20208 citationsauthor #7
Multiparametric Analysis of Longitudinal Quantitative MRI Data to Identify Distinct Tumor Habitats in Preclinical Models of Breast Cancer
202042 citationsauthor #4
Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme
202020 citationsauthor #9
Abstract 2775: Her2 expression level is positively correlated with paclitaxel response in human breast cancer xenograft mouse model
20200 citationsauthor #6
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
20200 citationsauthor #7
Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge
202010 citationsauthor #11
Abstract 5485: Patient-specific neoadjuvant regimens for breast cancer identifiedviaimage-driven mathematical modeling
20200 citationsauthor #6
Abstract PD9-07: The rate of parenchymal enhancement during DCE-MRI reflects response to neoadjuvant therapy
20200 citationsauthor #4
Abstract P2-01-01: Evaluating the order of treatments to enhance efficacy in a murine model of triple negative breast cancer with quantitative imaging
20200 citationsauthor #4
Abstract 6189: Identifying efficacy of targeted HER2 antibodies in sensitization of HER2+ breast cancer to fractionated radiation
20200 citationsauthor #4
Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data
202045 citationsauthor #7
Abstract P2-16-17: Optimizing neoadjuvant regimens for individual breast cancer patients generated by a mathematical model utilizing quantitative magnetic resonance imaging data: Preliminary results
20204 citationsauthor #5
Imaging for Response Assessment in Cancer Clinical Trials.
202033 citationsauthor #1
Abstract P6-02-04: Investigating the feasibility of performing quantitative DCE-MRI in an abbreviated breast examination
20200 citationsauthor #6
Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
20207 citationsauthor #5
CD4 T-Cell Immune Stimulation of HER2+ Breast Cancer Cells in Response to Trastuzumab In Vitro
20200 citationsauthor #7
Abstract P1-01-02: Quantitative breast MRI to predict response to neoadjuvant therapy in community imaging centers: Preliminary results
20191 citationsauthor #1

TIMELINE

2010 0 citations

2011 195 citations

2012 304 citations

2013 42 citations

2014 227 citations

2015 37 citations

2016 37 citations

2017 453 citations

2018 174 citations

2019 172 citations

2020 191 citations

2021 169 citations

2022 103 citations

2023 70 citations

2024 54 citations

2025 18 citations

2026 0 citations

A. Sorace

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT